Serina Therapeutics, Inc. (SER)

8.14 -0.66 (-7.50%) At close: 04:00PM EDT

Serina Therapeutics, Inc.

601 Genome Way
Suite 2001
Huntsville, AL 35806
United States
256 327 0566
https://serinatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Steven A. Ledger	Interim CEO & Director	237.5k	N/A	1959
Dr. Tacey Viegas Ph.D.	COO & Secretary	356.53k	N/A	1958
Dr. Randall W. Moreadith M.D., Ph.D.	Chief Scientific Officer	433.88k	N/A	1955
Dr. Balkrishan Gill Ph.D.	Executive Chairman	N/A	N/A	1965
Ms. Eun-Jae Park CPA	Interim CFO & Chief Accounting Officer	N/A	N/A	1972

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama.

Corporate Governance

Serina Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.